Get the Stockscreener App
1.61
3.21%
0.05
After Hours:
1.50
-0.11
-6.83%
Inmed Pharmaceuticals Inc stock is traded at $1.61, with a volume of 54,130.
It is up +3.21% in the last 24 hours and up +1.90% over the past month.
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
See More
Previous Close:
$1.56
Open:
$1.56
24h Volume:
54,130
Relative Volume:
0.04
Market Cap:
$5.34M
Revenue:
$3.25M
Net Income/Loss:
$-8.34M
P/E Ratio:
-0.6251
EPS:
-2.5755
Net Cash Flow:
$-7.71M
1W Performance:
+2.55%
1M Performance:
+1.90%
6M Performance:
+42.48%
1Y Performance:
-44.67%
1-Day Range:
$1.56
$1.6866
1-Week Range:
$1.51
$1.6866
52-Week Range:
$0.575
$3.28
Inmed Pharmaceuticals Inc Stock (INM) Company Profile
Name
Inmed Pharmaceuticals Inc
Sector
Phone
(604) 669-7207
Address
1445-885 WEST GEORGIA ST., VANCOUVER
Compare INM vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INM
Inmed Pharmaceuticals Inc
|
1.61 | 5.14M | 3.25M | -8.34M | -7.71M | -2.5755 |
TAK
Takeda Pharmaceutical Co Adr
|
16.89 | 50.65B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.72 | 41.09B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.29 | 39.45B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.42 | 30.13B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
547.25 | 23.00B | 3.17B | 1.29B | 1.01B | 27.09 |
Inmed Pharmaceuticals Inc Stock (INM) Latest News
Price to sales forward of InMed Pharmaceuticals Inc. – NASDAQ:INM - TradingView
Enterprise value to revenue forward of InMed Pharmaceuticals Inc. – NASDAQ:INM - TradingView
Penny stock InMed Pharmaceuticals merger deal targets migraine pipeline - MSN
InMed Pharmaceuticals Inc. Actuals & Estimates (NASDAQ:INM) - TradingView
InMed Pharmaceuticals Inc (INM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
InMed Pharmaceuticals Inc (INM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
InMed Pharmaceuticals Inc. Cash Flow – DUS:MWG - TradingView
Dilution adjustment of InMed Pharmaceuticals Inc. – DUS:MWG - TradingView
Current ratio of InMed Pharmaceuticals Inc. – DUS:MWG - TradingView
Total revenue of InMed Pharmaceuticals Inc. – DUS:MWG - TradingView
Basic earnings per share (basic EPS) of InMed Pharmaceuticals Inc. – DUS:MWG - TradingView
MWG Stock Price and Chart — DUS:MWG - TradingView
InMed Pharmaceuticals Inc (INM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
InMed Pharmaceuticals Inc (INM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
InMed Pharmaceuticals Inc (INM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
InMed Pharmaceuticals Inc (INM) Valuation: PE, PB & Fair Value Analysis - TradingKey
InMed Pharmaceuticals Inc (INM) Institutional Confidence - TradingKey
InMed Pharmaceuticals Inc (INM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
InMed Pharmaceuticals Inc (INM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
InMed-Mentari migraine merger backed by $290 million financing reshapes company strategy (INM) - MSN
InMed Pharmaceuticals Regains Nasdaq Listing Compliance Status - The Globe and Mail
Vivo Opportunity funds disclose major InMed (INM) insider share holdings - Stock Titan
Vivo Opportunity Fund Holdings Discloses Investment at InMed Pharmaceuticals with 21.7% Stake - TradingView
InMed Regains Nasdaq $1.00 Bid-Price Compliance After 10 Consecutive Business Days - TradingView
Nasdaq confirms InMed (NASDAQ: INM) back in minimum bid-price compliance - Stock Titan
InMed Pharmaceuticals (INM) Q3 2025 Earnings: Narrower Loss Reported With No Revenue StreamWeak Earnings Momentum - newsline.com
InMed Pharmaceuticals Regains Compliance With Nasdaq Continued Listing Requirements - Moomoo
InMed Pharmaceuticals (INM) Pushes Higher: Testing Resistance at $1.66 After Mild GainsDescending Triangle - newsline.com
ADAR1/Manager Daniel Schneeberger reports 24.1% stake in InMed (NASDAQ: INM) - Stock Titan
InMed Pharmaceuticals regains Nasdaq compliance - Investing.com UK
InMed Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com Australia
InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements - TMX Newsfile
InMed keeps Nasdaq spot after meeting $1 share-price rule - Stock Titan
Squadron Capital Management LLC Acquires 325,000 Shares in InMed Pharmaceuticals Inc - GuruFocus
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
InMed Highlights INM-901 Alzheimer’s Data in Q3 Update - TipRanks
Squadron Master Fund discloses 9.8% stake in InMed Pharmaceuticals (INM) - Stock Titan
Halper Sadeh LLC is Investigating Whether D, AVB, INM, EQR are Obtaining Fair Deals for their Shareholders - GlobeNewswire
INMInMed Pharmaceuticals Inc Stock Price and Quote - Finviz
InMed Pharmaceuticals (INM) Holds Steady Near Key Support LevelsSentiment Shift - The Legal Advocate
InMed Pharmaceuticals (INM) Holds Near Support Amid Quiet Trading SessionShort Setup Alerts - newsline.com
INM | InMed Pharmaceuticals Inc. Common Insider Trading - Quiver Quantitative
InMed Pharmaceuticals Q3 2025 Earnings: Continued Losses as Stock DeclinesTrough Earnings Signal - Newser
InMed Pharmaceuticals Q3 2025 Earnings: Net Loss Widens Amid Pipeline FocusFree Market Insights - Newser
InMed Pharmaceuticals and Mentari Announce Merger AgreementThe Legal Advocate - The Legal Advocate
InMed Pharmaceuticals Shares Surge Following Mentari Merger Announcement - HarianBasis.co
ADAR1-managed funds add 468,551 InMed (INM) shares in open-market buys - Stock Titan
InMed (INM) major holder ADAR1 reports 331,449 indirect shares on Form 3 - Stock Titan
InMed Pharmaceuticals Merges with Mentari Therapeutics to Target Migraine Prevention - HarianBasis.co
INM Stock Alert: What to Know as InMed, Mentari Announce Merger - Barchart.com
/C O R R E C T I O N -- InMed Pharmaceuticals/ - PR Newswire
Inmed Pharmaceuticals Inc Stock (INM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Inmed Pharmaceuticals Inc Stock (INM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Vivo Opportunity, LLC | 10% Owner |
Jul 02 '26 |
Buy |
1.55 |
1,607 |
2,491 |
724,395 |
| Vivo Opportunity, LLC | 10% Owner |
Jun 30 '26 |
Buy |
1.54 |
600 |
924 |
718,989 |
| Vivo Opportunity, LLC | 10% Owner |
May 20 '26 |
Buy |
1.56 |
56,210 |
87,688 |
543,129 |
| Vivo Opportunity, LLC | 10% Owner |
Jun 05 '26 |
Buy |
1.57 |
55,011 |
86,367 |
688,926 |
| Vivo Opportunity, LLC | 10% Owner |
May 21 '26 |
Buy |
1.69 |
34,000 |
57,460 |
574,011 |
| Vivo Opportunity, LLC | 10% Owner |
Jun 08 '26 |
Buy |
1.52 |
32,500 |
49,400 |
718,444 |
| Vivo Opportunity, LLC | 10% Owner |
Jun 02 '26 |
Buy |
1.52 |
22,848 |
34,729 |
625,766 |
| Vivo Opportunity, LLC | 10% Owner |
May 29 '26 |
Buy |
1.57 |
17,796 |
27,940 |
590,175 |
| Vivo Opportunity, LLC | 10% Owner |
Jun 01 '26 |
Buy |
1.55 |
16,336 |
25,321 |
605,013 |
| Vivo Opportunity, LLC | 10% Owner |
Jun 03 '26 |
Buy |
1.55 |
7,783 |
12,064 |
632,835 |
1.03%
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):